Benjamin Reinmann, M.D., says that the joint replacement market is moving away from the implant toward services driven by technology and keeping value-based patient care on the radar.
OrthogenRx markets GenVisc 850 and TriVisc biologic products. OrthogenRx executes at a level of efficiency that allows them to invest in pricing programs.
DJO continued its strategic move into the highly fragmented foot and ankle market with the acquisition of Trilliant Surgical.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
